Advertisement

Topics

Clovis, execs pay up to settle charges of misleading investors

04:25 EDT 19 Sep 2018 | BioPharmaDive

The SEC had accused Clovis, along with its CEO and former CFO, of knowingly misrepresenting the efficacy of its once lead cancer candidate rociletinib.

Original Article: Clovis, execs pay up to settle charges of misleading investors

NEXT ARTICLE

More From BioPortfolio on "Clovis, execs pay up to settle charges of misleading investors"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...